Methoxamine
 | |
| Clinical data | |
|---|---|
| Trade names | Vasoxine, Vasoxyl, Vasylox, others |
| Other names | Methoxamedrine; 2,6-Dimethoxy-β-hydroxy-α-methylphenethylamine; 2,6-Dimethoxy-β-hydroxyamphetamine |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral, injection[1] |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 3 hours |
| Excretion | Urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.006.244 |
| Chemical and physical data | |
| Formula | C11H17NO3 |
| Molar mass | 211.261 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Methoxamine, sold under the brand names Vasoxine, Vasoxyl, and Vasylox among others, is a sympathomimetic medication used as an antihypotensive agent.[2][3][4][5] It has mostly or entirely been discontinued.[6]
The drug is an α1-adrenergic receptor agonist.[4][additional citation(s) needed]
Medical uses
[edit]The long duration of action of methoxamine has been said to have rendered it obsolete in modern clinical practice.[2]
Pharmacology
[edit]Methoxamine is an α1-adrenergic receptor agonist.[2] It is described as a long-acting α1-adrenergic receptor agonist and this is contrasted with phenylephrine which is said to be short-acting.[2] Phenylephrine is 5 to 10 times more potent than methoxamine and has a 3-fold higher maximal effect.[2]
Chemistry
[edit]Methoxamine, also known as 2,6-dimethoxy-β-hydroxy-α-methylphenethylamine or as 2,6-dimethoxy-β-hydroxyamphetamine, is a substituted phenethylamine and amphetamine derivative.[3]
It is somewhat similar in chemical structure to those of desglymidodrine (3,6-dimethoxy-β-hydroxyphenethylamine), dimetofrine (3,5-dimethoxy-4,β-dihydroxy-N-methylphenethylamine), 2,5-dimethoxyamphetamine (2,5-DMA), and butaxamine ((1S,2S)-3,6-dimethoxy-β-hydroxy-N-tert-butylamphetamine).
History
[edit]Methoxamine was synthesized by 1944.[3] It was marketed in the United States by 1949.[1]
Society and culture
[edit]Names
[edit]Methoxamine is the generic name of the drug and its INN and BAN, while méthoxamine is its DCF and methoxamina is its DCIT.[3][4][6] In the case of the hydrochloride salt, its generic name is methoxamine hydrochloride and this is its USAN, BANM, and JAN.[3][4][7][6] A synonym of methoxamine is methoxamedrine.[4] The drug has been sold under brand names including Idasal, Mexan, Pressomin, Vasosterol, Vasoxine, Vasoxyl, and Vasylox.[3][4][6]
Availability
[edit]Methoxamine has been marketed in Canada, the Czech Republic, Ireland, Japan, Spain, the United Kingdom, and the United States and was available in these countries in 2000.[4][6] However, it was discontinued in Canada and the United Kingdom by 2004.[7] It has also been discontinued in the United States.[1] By 2016, methoxamine appeared to remain available only in Japan.[6]
References
[edit]- ^ a b c "Drugs@FDA: FDA-Approved Drugs". accessdata.fda.gov. Retrieved 1 September 2024.
- ^ a b c d e Thiele RH, Nemergut EC, Lynch C (August 2011). "The physiologic implications of isolated alpha(1) adrenergic stimulation". Anesth Analg. 113 (2): 284–296. doi:10.1213/ANE.0b013e3182124c0e. PMID 21519050.
- ^ a b c d e f Elks, J. (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 788. ISBN 978-1-4757-2085-3. Retrieved 2024-09-01.
- ^ a b c d e f g Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 669. ISBN 978-3-88763-075-1. Retrieved 2024-09-01.
- ^ Pazdernik TL, Kerecsen L (2007) [2003]. "5". In Goljan EF (ed.). Pharmacology. Rapid Review (Second ed.). Philadelphia, PA: Mosby-Elsevier. p. 39. ISBN 978-0-323-04550-6.
- ^ a b c d e f "Methoxamine". 20 October 2012. Archived from the original on 3 March 2016. Retrieved 1 September 2024.
{{cite web}}: CS1 maint: unfit URL (link) - ^ a b Schweizerischer Apotheker-Verein (2004). Index Nominum: International Drug Directory. Medpharm Scientific Publishers. p. 779. ISBN 978-3-88763-101-7. Retrieved 1 September 2024.